Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

APELLIS PHARMACEUTICALS, INC.

(APLS)
  Report
Delayed Nasdaq  -  04:00 2022-09-30 pm EDT
68.30 USD   +4.42%
09/30Aao 2022 : Treatment of Geographic Atrophy Secondary to AMD with Pegcetacoplan: Two-Year Outcomes from the Randomized Phase 3 OAKS and DERBY Trials
PU
09/30Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Function in High-Risk Areas of the Retina in Patients with Geographic Atrophy (GA) at AAO Annual Meeting
GL
09/30Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Function in High-Risk Areas of the Retina in Patients with Geographic Atrophy (GA) at AAO Annual Meeting
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Business Summary
Logo Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that is focused on developing therapeutic compounds to treat disease through the inhibition of the complement system. The Company is developing pegcetacoplan with Sobi for systemic administration in several indications, including paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy, immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, cold agglutinin disease, and hematopoietic stem cell transplantation thrombotic microangiopathy. The Company's advanced clinical programs targeting component 3 with Phase III clinical trials of its lead product candidate, pegcetacoplan, in multiple indications. Pegcetacoplan is a conjugate of a compstatin analogue, formulated both for ophthalmological administration by injections directly into the eye, and systemic administration by subcutaneous injection, which is an injection into the tissue under the skin.

Number of employees : 476 people.
Sales per Business
20202021Delta
Novel Therapeutic Compounds250.65100%66.56100% -73.44%
USD in Million
Sales per region
20202021Delta
United States250.65100%66.56100% -73.44%
USD in Million
Managers
Name Title Age Since
Cedric Francois President, Chief Executive Officer & Director 48 2009
Timothy Sullivan Chief Financial Officer & Treasurer 50 2017
Pascal Deschatelets Chief Scientific Officer 51 -
Federico Grossi Chief Medical Officer 46 -
Nur Nicholson Chief Technical Operations Officer 52 2020
Ahmad Sadr Vice President-Technical Operations - 2017
Adam Townsend Chief Commercial Officer 44 2018
Thomas Lackner Senior Vice President & Head-Europe - 2019
Lukas Scheibler, Dr. Chief Innovation Officer 50 2019
Jeffrey Eisele, Dr. Chief Development Officer - 2020
Members of the board
Name Title Age Since
Lok Chung Chan Chairman 70 2013
Alec Machiels Independent Director 48 -
Andrew Sinclair Dunlop Independent Director 49 2010
Stephanie Monaghan O'Brien Independent Director 62 2013
Paul R. Fonteyne Independent Director 60 2020
Cedric Francois President, Chief Executive Officer & Director 48 2009
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 109,865,305 92,826,588 84.5% 0 0.0% 84.5%
Shareholders
NameEquities%
Morningside Group Ltd. 12,806,342 11.7%
Wellington Management Co. LLP 11,542,743 10.5%
Avoro Capital Advisor LLC 9,805,000 8.92%
T. Rowe Price Associates, Inc. (Investment Management) 8,679,813 7.90%
The Vanguard Group, Inc. 8,496,067 7.73%
Ecor1 Capital LLC 5,183,431 4.72%
SSgA Funds Management, Inc. 3,496,925 3.18%
HHLR Advisors Ltd. 2,929,708 2.67%
Octagon Capital Advisors LP 2,583,059 2.35%
Jennison Associates LLC 2,298,347 2.09%
Company contact information
Apellis Pharmaceuticals, Inc.
100 5th Avenue
Waltham, MA 02451-8703

Phone : +1.617.977.5700
Web : http://www.apellis.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Apellis Pharmaceuticals, Inc.